啟明醫療(2500.HK)首日上市收漲30.45% 市值169億港元
格隆匯12月10日丨啟明醫療(2500.HK)首日上市高開21.22%,最終收報43.05港元,漲30.45%,成交21.07億港元,最新總市值169億港元。

該股發行價33港元,認購倍數312.42倍。
根據弗若斯特沙利文的資料,按2018年TAVR產品植入量計,啟明在中國的市場份額為79.3%。其自主研發的產品VenusA-Valve是首個獲NMPA批准及在中國進行商業化的TAVR產品。公司在大型未開發及快速增長的中國經導管心臟瓣膜行業上是市場領導者。
不過,由於員工成本和研發成本的增加,公司虧損淨額連年增加,2017年至2018年以及截至2019年5月31日止5個月期內虧損分別為1.58億元、3.01億元以及1.38億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.